Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992899 · ClinicalTrials.gov registry record · Phase 3
Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder
A Phase 3 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
NCT02992899: Completed Phase 3 study, sponsored by Emory University.
NCT02992899 is a Phase 3 study that has completed, run by Emory University. The registered enrollment target is 56 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02992899, a Phase 3 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
Study Summary
The tasks of the project are to map the potency and kinetics of the neurologic, autonomic peripheral, inflammatory, and behavioral responses to vagal nerve stimulation (VNS) vs. sham treatment, at baseline and in response to stressful traumatic scripts related to personal traumatic events, as well as a series of other stressors.
Primary Outcome
IL6 level will be collected via blood draw. Change is defined as the difference in IL6 level from baseline to post emotional stress testing.
Interventions
- DEVICE GammaCore/electroCore non-invasive VNS device
- DEVICE Sham gammaCore/electroCore
- DRUG O-15 water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2019-09-21 |
| Phase | Phase 3 |
What the finished NCT02992899 record still lists
NCT02992899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which GammaCore/electroCore non-invasive VNS device is the first listed.
NCT02992899 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02992899 about?
NCT02992899 is a clinical study titled "Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder". The tasks of the project are to map the potency and kinetics of the neurologic, autonomic peripheral, inflammatory, and behavioral responses to vagal nerve stimulation (VNS) vs. sham treatment, at baseline and in response to stressful traumatic scripts related to personal traumatic events, as well a...
What is the current status of trial NCT02992899?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2017-04-19. Estimated completion is 2019-09-21.
What interventions are being tested in trial NCT02992899?
The interventions under investigation include: GammaCore/electroCore non-invasive VNS device (DEVICE), Sham gammaCore/electroCore (DEVICE), O-15 water (DRUG).
Who is sponsoring clinical trial NCT02992899?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02992899's enrollment target sits among peer trials
56 1827th of 2000 higher than 167 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI